SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase versus the prior year, driven by sales of its QUELIMMUNE therapy for pediatric acute kidney injury. The NEUTRALIZE-AKI pivotal trial has enrolled 223 of 339 targeted patients, with completion anticipated by year-end or Q1 2027, positioning the company for a PMA submission near the end of 2027.
Key figures
- Revenue
- 615000
- Revenue Yoy
- 82%
- Gross margin
- 91%
- Cash position
- 6959000
- Trial patients enrolled
- 223
- Trial target enrollment
- 339
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.